Supplemental Table 2: Univariate and multivariable Cox regression analyses for overall survival in patients with stage IV NSCLC treated with combination therapy: Within 30 days vs 30-61 days. Propensity-score matching analysis

Factors Univariate Multivariate

 HR (95% CI) HR (95% CI)

 P value P value

Institution Academic 1.05 (0.83-1.33), 0.66 1.11 (0.87-1.40), 0.41

 Others (Ref)

Age <70 0.80 (0.63-1.00) , 0.05 0.80 (0.63-1.01) , 0.06

 70≤ (Ref)

Sex Female 0.79 (0.72-0.85) , <0.01 0.71 (0.56-0.89), 0.003

 Male (Ref)

Race Others 0.84 (0.57-1.20), 0.35 0.85 (0.56-1.23), 0.39

 White (Ref)

CD Score 0-1 0.83 (0.53-1.38), 0.45 0.80 (0.51-1.35), 0.39

 2≤ (Ref)

Year of Diagnosis 2018 1.04 (0.84-1.30), 0.72 1.07 (0.37-2.38), 0.90

 2017 (Ref)

Histology Adenocarcinoma 0.68 (0.54-0.85), <0.01 0.74 (0.58-0.94), 0.01

 Others (ref)

Clinical T stage Others 1.02 (0.82-1.27), 0.86 1.05 (0.84-1.32), 0.68

 T3-4 (Ref)

Clinical N Stage Others 0.87 (0.69-1.09), 0.22 0.82 (0.64-1.04), 0.1

 N2-3 (Ref)

Clinical M stage Other 0.75 (0.59-0.95), 0.02 0.84 (0.65-1.09), 0.19

 M1BC (Ref)

Surgery Yes 1.23 (0.44-2.67), 0.65 1.06 (0.37-2.38), 0.90

 No (Ref)

Radiation No 0.97 (0.76-1.25), 0.79 0.91 (0.71-1.17), 0.46

 Yes (Ref)

Immunotherapy 0-30 days 0.73 (0.59-0.90), <0.01 0.73 (0.59-0.91), <0.01

 31-60 days (Ref)

Brain metastasis No 0.97 (0.76-1.25), 0.79 0.97 (0.72-1.31), 0.86

 Yes (Ref)

Liver metastasis No 0.63 (0.49-0.82), <0.01 0.64 (0.48-0.84), <0.01

 Yes (Ref)

NSCLC, non-small cell lung cancer; HR, hazard ratio; CI, confidence interval; Ref, reference; CD, Charlson Comorbidity; NOS, not otherwise specified.